COMVITA LIMITED INVESTOR PRESENTATION 2013 Neil Craig, Chairman, Ph Brett Hewlett, Chief Executive O fficer, Ph.
|
|
- Arline Sullivan
- 5 years ago
- Views:
Transcription
1 COMVITA LIMITED INVESTOR PRESENTATION 2013 Neil Craig, Chairman, Ph Brett Hewlett, Chief Executive O fficer, Ph
2 2014 Half Year Update NZD $000 S 6 MONTHS ENDED 30 SEPT MONTHS ENDED 30 SEPT 2012 Sales 43,362 45,434 EBITDA * 1,893 5,314 Net (loss)/profit after tax - NPAT (790) 2,386 Earnings per share NPAT (NZ Cents) (2.70) 8.39 Dividend per share (NZ Cents) *EBITDA: Earnings Before Interest, Tax, Depreciation and Amortisation 2
3 Achievements 2014 Half Year Rebuilding inventory of Manuka honey Expansion of 100% owned apiary operations New acquisition in Gisborne - Tawari Apiaries Olive Leaf planting programme at our new farm Derma Sciences invests $8.9m Opening of Auckland Concept store and Comvita tourism venture, Experience Comvita System projects initiated POS, Demand Planning, Apiary Management, E-Commerce Factory expansion and Paengaroa site development Outlook Second half year sales expected to be >60% of total Strong growth in key Asian markets Medihoney TM wound care sales growth Net earnings and Sales expected to exceed
4 The following pages are from the May 2013 Investor Presentation 4
5 Comvita Results at Upper End of Guidance Financial results for the year to 31 March 2013 $M 2012 $M Change % Revenue % EBITDA * (5.2%) Net profit after tax (9.8%) Earnings per share (cents) (11.7%) Dividends (cents) (7.1%) *EBITDA: Earnings Before Interest, Tax, Depreciation and Amortisation 5
6 Balance Sheet Very strong position, significant borrowing headroom for possible acquisitions and for capital expenditure. Any such acquisitions would need to be demonstrably earnings positive per share in the short-term. Key Ratios Shareholder equity ratio 60% Net debt 25m Net debt to EBITDA 1.7 x Net interest cover 9.4 x Net debt to equity ratio 31% 6
7 Financial Performance Group Revenue EBITDA ** $31m $39m $85m $82m 2006 $65m * $71m $96m $103m 2008 $0.4m * $4.8m $15.5m $14.7m $4.1m $5.3m $6.3m $11.2m * 15 month period, due to change in balance date. ** EBITDA Earnings before interest, tax, depreciation, amortisation, impairments and fair value movements of financial instruments. 7
8 Achievements Group sales grew by 8% Strong growth in Hong Kong, China, Korea Assertive pricing and continued strong demand underpins premium brand position in Asian markets Increased share of Manuka honey supply under direct ownership, through Apiary acquisition Investment in Fresh Olive Leaf Extract R&D pays-o ff with positive results Continued strong growth in the medical honey category SUPPLY CHAIN MARKET DEVELOPMENT SCIENCE AND RESEARCH Acquisition of Whanganui-based apiary business lifts share of honey source under ownership to >30% Acquisition of additional property for Olive Leaf production Paengaroa HQ site future-proof development project underway Strong growth in Hong Kong and China confirms premium position of Comvita brand Korea retail presence bolstered with a total of 12 retail outlets in major department stores >25% of sales now made direct to consumers via retail and internet Premium branding helps insulate impact of Manuka honey shortages and cost increases Clinical trial results for fresh Olive Leaf Extract shows benefit for those at risk of diabetes New health claim and product o ffering for fresh Olive Leaf Extract opens new market opportunities International research papers provide further support for wound healing technologies China propolis Blue Hat registration 8
9 Sales by Region $45.3m $24.5m $21.2m $6.4m $6.1m ASIA AUSTRALIA NEW ZEALAND UK/EUROPE NORTH AMERICA 9
10 Sales by Category 42% 48% 5% 4% 1% HEALTHCARE FUNCTIONAL FOODS PERSONAL CARE MEDICAL OTHER 10
11 Outlook Restored earnings growth Continued strong growth in key Asian markets Online and retail sales developments Continued e fforts for security of supply for Manuka Honey Opening of Comvita Tourism Experience, Bay of Plenty Growing greater capacity for fresh Olive Leaf Extract Further diversification of ingredient platform leading to exciting new business development opportunities 11
12 Evolving Our Business Sales $103m $31m Gross Margin% 56% 34% EBITDA $14.7m $4.1m Assets $137m $50m Employees % Sales Export 80% 60% % Sales via Distributors 16% 85% % Sales Honey 47% 65% % Sales B2C 26% 3% 12
13 Market Segments Manufactures, markets and distributes natural health and beauty products across four key broad market segments 42% 48% 5% 4% HEALTHCARE Variety of healthcare products designed to compete with traditional over-the-counter (OTC) pharmaceutical products Key Products: - Olive Leaf Extract - Propolis - Winter Wellness - Bee Pollen - Royal Jelly FUNCTIONAL FOODS Worlds largest manufacturer and marketer of Manuka honey Invest in ongoing research and development to maintain premium brand positioning Key Products: -UMF Manuka Honey - Apple Cider Vinegar - Honeygar PERSONAL CARE Comprises home-based woundcare, therapeutic skincare and oral care products Key Products: -Manuka Honey skincare - Olive Leaf Extract skincare - Propolis toothpaste and Propolis tooth gel MEDICAL * Does not total to 100% as it excludes Other business unit which accounts for remainder for the 12 months to 31 March 2013 Medical-grade leptospermum (Manuka) honey for treatment of chronic wounds Global licensing deal for Medihoney with Derma Sciences Key Products: -Medihoney medical products 13
14 Value Added Generic Comvita branded health honey Medical Skincare $5 * $14 $104 $330 $500 * Retail selling price per 250g equivalent of raw Manuka honey 14
15 Bottom Standard Layout Without Frond 15
16 Manuka Honey Bottom Standard Layout Without Frond The worlds largest processor of Manuka honey 16,000 hives specialist Manuka honey producer Circa 35,000 hives under contracted supply >30% of Comvita s honey supply under ownership High-tech medical honey extraction facility Manuka planting and land development programmes Plant breeding programme and agronomics 16
17 Fresh Olive Leaf Bottom Standard Layout Without Frond 580,000 olive trees on 157 ha plantation Plant variety selection and screening programme Acquisition of second olive grove, with 7,000 existing organic olive trees on 85 ha - Plans to plant 400,000 trees in next two years Only totally integrated manufacturer - Fresh picked, fresh processed 17
18 Specialist Manufacturing Bottom Standard Layout Without Frond World first honey testing capability UPLC based, in-house laboratory Ethanol and water extraction for bio-actives Honey processing, liquid formulations and packing Exclusive third-party relationships 18
19 Natural Health Innovators Bottom Standard Layout applications Without Frond FDA approved and CE marked medical devices A total of 61 patents or patents pending covering 13 di fferent unique innovations in wound care Global distribution via licensing agreement with specialty US wound care company Derma Sciences Inc. Fresh Olive Leaf Extract: patent position taken around Fresh Olive Leaf Extract for blood sugar control in at-risk adult males 19
20 Bottom Standard Layout Without Frond Research Circa $2.7m p.a. in research and development Isolation and identification of lead bioactive compounds Clinical trials New product development Regulatory approvals for health claims Development of tests for honey quality and authenticity Plant breeding programmes Field agronomic trials Processing methodologies and optimisation Partnership with The University of Auckland and part of global science network 20
21 Building a Premium Global Brand Bottom Standard platforms Layout Without Frond Brand reputation in Asia allows significant price premium over nearest competitors Brand o ffer on focussed, di fferentiated ingredient Brand story has great level of meaning with customers Source and e fficacy of product range Growth and awareness opportunity through tapping into New Zealand tourism via brand experiences 21
22 Bottom Standard Layout - Asian focus Without Frond Consumer Needs Focus Design Large scope to further broaden product o ffering - Foods, healthcare, personal care, medical Very large global natural products sector Global trends support growth - Ageing populations - Growing preference to self-medicate - Increased incidence of degenerative diseases - Tightening regulations eliminating less scrupulous competition 22
23 Diversity and Reach of Direct Channels a Real Strength! Established wholesale business in UK, Australia, NZ Bottom Standard! Layout Without Frond!! Asia 90% direct to consumers 35 dedicated stores and a total of 400 branded retail locations in China 82 Comvita retail locations, 54 in Hong Kong, 12 in Taiwan, 12 in Korea, 2 in UK and 2 in NZ!! Web sales growing online in all Comvita markets, with total online sales nearly doubling in the last 12 months Medical products via specialist distributor 23
24 Bottom Standard Layout Without Frond 24
25 Auckland Concept Store 25
26 Experience Comvita 26
27 Manuka Honey Without Frond 27
28 Propolis & Royal Jelly Without Frond 28
29 Winter Wellness Without Frond 29
30 Fresh Olive Leaf Complex 30
31 Skin Care Without Frond 31
32 Medihoney Without Frond 32
33
Welcome and Agenda 1. Welcome / Apologies Neil Craig 2. Chairman s Review Neil Craig 3. CEO Review Brett Hewlett 4. Derma Sciences Inc Update Edward
1 Welcome and Agenda 1. Welcome / Apologies Neil Craig 2. Chairman s Review Neil Craig 3. CEO Review Brett Hewlett 4. Derma Sciences Inc Update Edward J. Quilty 5. Resolution 1: Reports and Financial Statements
More informationINVESTOR PRESENTATION FY17 AND OUTLOOK FY18
INVESTOR PRESENTATION FY17 AND OUTLOOK FY18 AUGUST 2017 CHIEF EXECUTIVE OFFICER, SCOTT COULTER, 021 386 988 CHIEF COMMERCIAL OFFICER, MARK SADD, 027 707 9698 IMPORTANT NOTICE This presentation is given
More informationANNUAL SHAREHOLDERS MEETING 18 OCTOBER 2017
ANNUAL SHAREHOLDERS MEETING 18 OCTOBER 2017 1 IMPORTANT NOTICE This presentation is given on behalf of Comvita Limited. Information in this presentation: should be read in conjunction with, and is subject
More informationI N V E S T O R P R E S E N T A T I O N A U G U S T
I N V E S T O R P R E S E N T A T I O N A U G U S T 2 0 1 6 CHIEF EXECUTIVE OFFICER, SCOTT COULTER, 021 386 988 CHIEF FINANCIAL OFFICER, MARK SADD, 027 707 9698 Investor Presentation August 2016 1 I M
More informationINVESTOR PRESENTATION HY18 AND OUTLOOK FY18
INVESTOR PRESENTATION HY18 AND OUTLOOK FY18 FEBRUARY 2018 CHIEF EXECUTIVE OFFICER, SCOTT COULTER, 021 386 988 CHIEF COMMERCIAL OFFICER, MARK SADD, 027 707 9698 IMPORTANT NOTICE This presentation is given
More informationCOMVITA LIMITED AND GROUP CONDENSED INTERIM FINANCIAL STATEMENTS
COMVITA LIMITED AND GROUP CONDENSED INTERIM FINANCIAL STATEMENTS For the 6 months ended CONTENTS 2 4 5 6 7 8 9 10 20 FROM THE CHAIRMAN AND CHIEF EXECUTIVE DIRECTORS DECLARATION CONDENSED INTERIM INCOME
More informationCOMVITA LIMITED AND GROUP FINANCIAL STATEMENTS
COMVITA LIMITED AND GROUP FINANCIAL STATEMENTS For the 15 month s end ed 30 June 2016 CONTENTS 2 3 4 5 6 7 8 39 40 45 DIRECTORS DECLARATION INCOME STATEMENT STATEMENT OF COMPREHENSIVE INCOME STATEMENT
More informationCOMVITA LIMITED AND GROUP. Financial Statements. 31 March 2014
COMVITA LIMITED AND GROUP Financial Statements 31 March 2014 Contents Directors Declaration 2 Income Statement 3 Statement of Comprehensive Income 4 Statement of Changes in Equity 5 6 Statement of Financial
More informationComvita Financial Statements PI COMVITA LIMITED AND GROUP FINANCIAL STATEMENTS
Comvita Financial Statements 2017 - PI COMVITA LIMITED AND GROUP FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2017 Comvita Financial Statements 2017 - PII Comvita Financial Statements 2017 - P1 CONTENTS
More informationCOMVITA LIMITED AND GROUP FINANCIAL STATEMENTS
COMVITA LIMITED AND GROUP FINANCIAL STATEMENTS For the year ended 31 March 2015 Comvita Financial Statements 2015 - P2 CONTENTS P4 P5 P6 P7 P8 P9 P10 P52 P53 P58 DIRECTORS DECLARATION INCOME STATEMENT
More informationCOMVITA LIMITED AND GROUP FINANCIAL STATEMENTS
COMVITA LIMITED AND GROUP FINANCIAL STATEMENTS For the year ended 31 March 2015 Comvita Financial Statements 2015 - P2 CONTENTS P4 DIRECTORS DECLARATION P5 INCOME STATEMENT P6 STATEMENT OF COMPREHENSIVE
More informationEBOS Group Ltd. For personal use only. Results presentation Financial Year ended 30 June August 2016
EBOS Group Ltd Results presentation Financial Year ended 30 June 2016 Patrick Davies John Cullity Chief Executive Officer Chief Financial Officer 25 August 2016 Disclaimer The information in this presentation
More informationFor personal use only
ASX Code: A2M NZX Code: ATM 20 July 2015 NZX/ASX Market Release Record Australian earnings, Exceptional a2 Platinum infant formula growth, Positive progress in international markets With regard to recent
More informationBlackmores Half-Year Financial Results. Half-Year ended 31 December 2016
Blackmores Half-Year Financial Results Half-Year ended 31 December 2016 1 2 Invoiced Sales ($m) Second quarter showed strong improvement, though first half sales and profit down Improved Q2 sales up 16%
More informationHalf Year Report For the six months to 30 September 2017
Half Year Report For the six months to 30 September 2017 OPERATIONS REPORT 30 September 2017 OVERVIEW Blis Technologies Limited (Company) was formed to commercialise BLIS advanced probiotic bacteria in
More informationa2 Milk, a2 Platinum and The a2 Milk Company are trade marks of The a2 Milk Company Limited
a2 Milk, a2 Platinum and The a2 Milk Company are trade marks of The a2 Milk Company Limited Agenda 1. Result highlights 2. Group Infant Formula update 3. Regional update 4. Research and development 5.
More informationPaul Maguire Philip Bennett Paul Witheridge Managing Director Chief Financial Officer Chief Financial Officer
McPherson s Limited Results for the year to 30 June 2011 Paul Maguire Philip Bennett Paul Witheridge Managing Director Chief Financial Officer Chief Financial Officer McPherson s Limited McPherson s Limited
More informationFor personal use only
ASX Code: A2M NZX Code: ATM 17 February 2016 NZX/ASX Market Release Outstanding growth in infant formula drives record results for The a2 Milk Company Full year forecast revised upward Overview - financial
More informationFor personal use only
ABN 85 003 622 866 GPO Box 5015, Sydney NSW 2001 Level 1, 160 Pitt Street Mall, Sydney NSW 2000 ASX Appendix 4E Preliminary Final Report 31 st July 2015 Lodged with the ASX under Listing Rule 4.3A Contents
More informationComvita Limited and Group Financial Statements. For the year ended 31 March 2013
Comvita Limited and Group Financial Statements For the year ended 31 March 2013 Statutory information Principal activity The principal activity of the company
More informationFY16 Full Year Results Geoffrey Babidge August a2 Milk, a2 Platinum and The a2 Milk Company are trademarks of The a2 Milk Company Limited
FY16 Full Year Results Geoffrey Babidge August 24 2016 1 a2 Milk, a2 Platinum and The a2 Milk Company are trademarks of The a2 Milk Company Limited Results highlights Financial overview Group infant formula
More informationCorporate Presentation
Corporate Presentation The presentation herein may contain forward looking statements by the management of Best World International Ltd (BWI) that pertain to expectations for financial performance of future
More informationNEWS RELEASE FOR IMMEDIATE RELEASE
NEWS RELEASE FOR IMMEDIATE RELEASE Pumpkin Patch ready as markets improve Audited results for the 12 months ended 31 July 2009 Headline Financial Numbers July 2009 ($ 000) July 2008 ($ 000) Operating revenue
More informationWELCOME 55 th ANNUAL GENERAL MEETING BLACKMORES LTD 26 OCTOBER 2017
WELCOME 55 th ANNUAL GENERAL MEETING BLACKMORES LTD 26 OCTOBER 2017 CHAIRMAN S WELCOME Stephen Chapman Chairman 2 Marcus Blackmore AM Executive Director 3 GUEST SPEAKERS Blackmores Asia 4 CEO S YEAR IN
More informationIt s subsidiary CS&Co distributes international cosmetics, fragrances, skincare and haircare brands in New Zealand. Consumer Product Brands
TIL - Trilogy International Limited (NZX:TIL, ASX:TIL) is a cultivator of essential natural products and home fragrance brands: Trilogy Natural Products, ECOYA and Goodness Natural Beauty Lab in New Zealand
More informationRhinomed Limited Appendix 4E Preliminary Final Report
Preliminary Final Report Year Ended (Previous corresponding year: 30 June 2017) ABN 12 107 903 159 Results for announcement to the market Revenue from ordinary activities 26.3% to 2,169,176 Loss after
More informationFor personal use only
P: +61 8 6465 5500 EveInvestments W: www.eveinvestments.com.au 31 January 2018 Quarterly Review Highlights Eve Investments completes its 50% investment in Meluka Health. Meluka Health: Commenced branding
More informationFor personal use only
ABN: 55 009 686 435 FINANCIAL STATEMENTS Half Year ended 31 December 2015 Report of the Directors 1 Auditor s Independence Declaration 2 Independent Auditor s Review Report 3 Directors Declaration 4 Consolidated
More informationSCALES CORPORATION LIMITED GROWING YOUR DIVERSIFIED AGRIBUSINESS
SCALES CORPORATION LIMITED GROWING YOUR DIVERSIFIED AGRIBUSINESS 2017 Annual Shareholders Meeting 14 MR APPLE CONSUMER VIDEO AGENDA Welcome Chairman s review Managing Director s review Ordinary business
More informationAnnual Results Presentation: May Todd Hunter: Chief Executive Officer Aaron Saunders: Group Chief Financial Officer
Todd Hunter: Chief Executive Officer Aaron Saunders: Group Chief Financial Officer FY17 FINANCIAL HIGHLIGHTS Continuing To Deliver Growth Operating Revenue $252.4m 48% Record NPBT $24.6m 14% Strong NPAT
More informationAttached is the ASX / Media Release in relation to the results for the year ended 30 June 2018.
22 August 2018 McPherson s Limited (ASX: MCP) Manager, Company Announcements ASX Limited Level 4, 20 Bridge Street SYDNEY NSW 2000 Dear Sir ASX / Media Release and Webcast of FY18 Results Presentation
More informationTegel Group Holdings Limited
Tegel Group Holdings Limited FY17 Interim Results Presentation 15 December 2016 TEGEL GROUP HOLDINGS LIMITED FY17 INTERIM RESULTS 1 Disclaimer This presentation contains summary information about Tegel
More informationASX Announcement MAYNE PHARMA REPORTS 2018 HALF YEAR PERFORMANCE
23 February 2018 MAYNE PHARMA REPORTS 2018 HALF YEAR PERFORMANCE Revenue of $243.3m, a decrease of 17% on 1HFY17 Adjusted EBITDA of $70.2m, down 36% on 1HFY17 Reported EBITDA of $23.0m, down 82% on 1HFY17
More informationInvestor Presentation
NZX Code: ATM ASX Code: A2M 3 May 2017 NZX/ASX Market Release Investor Presentation Please find attached a presentation to be given today by The a2 Milk Company Limited at Macquarie s annual Australia
More informationResults for the Year ended 30 June 2012 Blackmores Limited ASX:BKL
Results for the Year ended 30 June 2012 Blackmores Limited ASX:BKL 10 th year of record sales and profit Group Sales up 11% to $261m Fourth Quarter record sales quarter $75m Another record profit year
More information20 August Geoffrey Babidge. Managing Director & CEO
20 August 2015 Geoffrey Babidge Managing Director & CEO FY15 Result Highlights Revenue growth 40% EBITDA growth 35% 1 Exceptional infant formula result Record Australia result Total revenue of $155.1 million,
More informationPRESS RELEASE. 13 September 2018 Aspen One
PRESS RELEASE Aspen Pharmacare Holdings Limited ( Aspen ) (Incorporated in the Republic of South Africa) (Registration Number 1985/002935/06) (Share code APN ISIN: ZAE000066692) 13 September 2018 Aspen
More informationKathmandu Holdings Limited
Kathmandu Holdings Limited New Zealand Stock Exchange Listing Rules Disclosure Half Year Report For the period ending 2018 Contents Appendix 1 Media Announcement Directors Report Interim Report (including
More informationConsolidated Settlement of Accounts for the Nine Months Ended December 31, 2009
The figures for these Financial Statements are prepared in accordance with the accounting principles based on Japanese law. Accordingly, they do not necessarily match the figures in the Annual Report issued
More informationFor personal use only
ABN: 55 009 686 435 Half Year ended 31 December 2016 Report of the Directors 1 Auditor s Independence Declaration 2 Independent Auditor s Review Report 3 Directors Declaration 4 Consolidated Statement
More informationFor personal use only
P: +61 8 6465 5500 EveInvestments W: www.eveinvestments.com.au 1 May 2017 EVE INVESTS IN PIONEERING CANNABIS HONEY & TEA TREE OIL COMPANY Highlights EVE enters a binding term sheet to acquire a 50% interest
More informationFor personal use only
31 January 2018 ASX Code: MXC December Quarterly Activity Report Major operational achievements across all three divisions, material contracts with near term revenue generation potential signed during
More informationASX Announcement. 16 November AGM Presentations
ASX Announcement 16 November 2016 AGM Presentations In accordance with the ASX Listing Rules and the Corporations Act 2001, attached are the presentations to be given at today s Annual General Meeting.
More informationFor personal use only. Lovisa Holdings Limited 2019 HALF YEAR
Lovisa Holdings Limited 2019 HALF YEAR SHANE FALLSCHEER CHRIS LAUDER MANAGING DIRECTOR CHIEF FINANCIAL OFFICER Some of the information contained in this presentation contains forward - looking statements
More informationDr Simon Kwok, JP Chairman & CEO
Chairman's Statement We will continue to expand our presence in the region and to grow at a prudent pace in both our overseas markets and in Mainland China. Dr Simon Kwok, JP Chairman & CEO 16 The fiscal
More informationCLSA Investors Forum. Hong Kong September a2 Milk, a2 Platinum and The a2 Milk Company are trademarks of The a2 Milk Company Limited
CLSA Investors Forum Hong Kong 11-12 September 2017 a2 Milk, a2 Platinum and The a2 Milk Company are trademarks of The a2 Milk Company Limited Disclaimer This presentation dated 11 September 2017 provides
More informationAFT PHARMACEUTICALS Investor Presentation: H1 FY2018 November 2017
AFT PHARMACEUTICALS : H1 FY2018 IMPORTANT NOTICE This presentation has been prepared by AFT Pharmaceuticals Limited ( AFT ), to provide a general overview of AFT. It is not prepared for any other purpose
More informationResults for the Year ended 30 June 2013 Blackmores Limited ASX:BKL
Results for the Year ended 30 June 2013 Blackmores Limited ASX:BKL Building Platforms for Growth Strong sales of $327m, up 25% in a very challenging year Good progress on building new platforms for growth
More informationRakon Limited Preliminary Financial Statements FY2017
Rakon Limited Preliminary Financial Statements FY2017 Table of Contents Table of Contents 1 Directors Report 2 Statement of Comprehensive Income 3 Statement of Changes in Equity 4 Balance Sheet 5 Statement
More informationWILMAR INTERNATIONAL LIMITED ANNUAL GENERAL MEETING. 28 April 2016
WILMAR INTERNATIONAL LIMITED ANNUAL GENERAL MEETING 28 April 2016 IMPORTANT NOTICE Information in this presentation may contain projections and forward looking statements that reflect the Company s current
More informationFiona is happy to do this slide
Fiona is happy to do this slide DISCLAIMER This presentation contains not only a review of operations, but also some forward looking statements about Sanford Limited and the environment in which the company
More informationMalcolm Jackman Elders Limited
Malcolm Jackman Elders Limited The New Elders Refocused Reorganised Recapitalised ASX Small & Mid Cap Conference 29 October 2009 Malcolm Jackman Chief Executive Officer Chief Executive Officer 2 The New
More informationChairman s AGM address
21 February 2018 Chairman s AGM address Today I will provide you with an update of the Group. This will include an overview of the Group s strategic direction and key points relating to HGL s financial
More informationTarget is to reach at least break-even by January 2015
Summary Results for the year are very disappointing Target is to reach at least break-even by January 2015 An in-depth and broad-ranging review was instigated early in 2012 Implementation of the resulting
More informationMarket Release November
Market Release November 23 2017 FINANCIAL RESULTS FOR HALF YEAR ENDED 30 SEPTEMBER 2017 AFT Pharmaceuticals Limited (NZX; AFT, ASX; AFP) today announced its half-year unaudited financial results for the
More informationOther products and technologies are currently in the research and development or pre-commercial stage. These technologies include:
The MD&A provides commentary on the results of operations for the six months ended June 30, 2012 and 2011, the financial position as at June 30, 2012, and the outlook of Ceapro Inc. ( Ceapro ) based on
More informationSunRice Grower & Shareholder Meetings Mr. Rob Gordon, CEO
SunRice Grower & Shareholder Meetings Mr. Rob Gordon, CEO June 2017 The situation leading up to 2012 and the subsequent Strategy Portfolio characteristics 2011 The 2012 Strategy 2 This strategy was responsible
More informationFull Year Results Presentation
Full Year Results Presentation 12 months ended 31 December 2010 8 March 2011 1 Agenda 1. Introduction and Highlights Ray King, Chief Executive 2. Financial Review Tom Singer, Group Finance Director 2.1
More informationIan Davis Nuplex Industries Limited
Ian Davis Nuplex Industries Limited Nuplex an industrial resins & specialties business ASX Small to Mid Caps Conference Hong Kong, 29 October 2009 John Hirst Managing Director 37 Who we are Nuplex is an
More informationNEW NORDIC HEALTHBRANDS AB (PUBL) NINE MONTH REPORT JANUARY - SEPTEMBER 2018
NEW NORDIC HEALTHBRANDS AB (PUBL) NINE MONTH REPORT JANUARY - SEPTEMBER 218 218 217 Net sales, ksek 296 77 258 97 112 697 88 315 Change in SEK, % 14.7% 9.7% 27.6% 4.2% Change in local currencies, % 1.%
More informationNZX, ASX and Media Release 20 November 2017 RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2017
NZX, ASX and Media Release 20 November 2017 RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2017 Metro Glass reports increased Australian contribution offset by softer than anticipated construction activity
More informationTegel Group Holdings Limited
Tegel Group Holdings Limited FY17 Full Year Results Presentation 27 June 2017 1 TEGEL GROUP HOLDINGS FY17 RESULTS PRESENTATION Disclaimer This presentation contains summary information about Tegel Group
More informationIntroductions. Chairman s comments. CEO presentation. General discussion / Q&A. Formal business of the meeting. Close and afternoon tea
Introductions Chairman s comments CEO presentation General discussion / Q&A Formal business of the meeting Close and afternoon tea 2 Chairman Executive Director CS&Co Representative Director Independent
More informationJamaica Producers Group Limited
( JP ) generated revenues of $8.82 billion in 2014 and earned profits attributable to JP shareholders of $358 million. Our revenues increased 14% over the prior year. Profits attributable to JP shareholders
More informationAFT PHARMACEUTICALS Investor Presentation
AFT PHARMACEUTICALS IMPORTANT NOTICE This presentation has been prepared by AFT Pharmaceuticals Limited ( AFT ), to provide a general overview of AFT. It is not prepared for any other purpose and must
More informationFor personal use only. FY16 Results Presentation
FY16 Results Presentation PAGE 1 Agenda 1. Highlights 2. FY16 Results Trading performance Balance sheet and cash flow Capital management 3. Business Update Our objectives The JB HI-FI model Store portfolio
More informationAnnual Results to 31 st January 2014
Annual Results to 31 st January 2014 o Improvement in performance and key trends o Turnaround gathered momentum in H2 as initiatives gained traction o New team performing well o Reduced operating expenses
More informationTruScreen Interim Report
2018 INTERIM REPORT TruScreen Interim Report 2018 1 CONTENTS Our Vision 03 Progress Against Strategic Goals 04 Half Year Results Snapshot 05 Chairman and CEO s Report 06 Interim Financial Statements 08
More informationEBOS Group Interim Report
1 EBOS Group Interim Report 31 DECEMBER 2017 EBOS Group Limited Interim Report 2018 2 EBOS Group has delivered record first half earnings, demonstrating the benefits of a diverse portfolio of Healthcare
More informationFor personal use only
ASX Announcement Freedom Foods Group Limited (ASX: FNP) FY 2013 Financial Results Freedom Foods Group Limited (FNP) today released the Company s preliminary final results for the full year ended 30 th
More informationKATHMANDU FY10 RESULTS PRESENTATION
KATHMANDU FY10 RESULTS PRESENTATION 1 CONTENTS Results Overview Key Line Items Country Results Cash Flow, Dividend, Balance Sheet FY11 Outlook Growth Strategy Update Questions 2 RESULTS OVERVIEW 3 RESULTS
More informationAnnual Shareholders Meeting 30 October 2018
Annual Shareholders Meeting 30 October 2018 Board of Directors Leadership Team A W (Alan) Clarke G C W (Grant) Biel S E F (Sarah) Haydon Retiring at today s meeting J M (John) Rae T H G (George) Adams
More informationImportant Notice. The sum totals throughout this presentation may not add exactly due to rounding differences.
Important Notice This presentation contains general information about Reliance Worldwide Corporation Limited s activities at the date of presentation (26 February 2018). It is information given in summary
More informationFor personal use only
P: +61 8 6465 5500 EveInvestments W: www.eveinvestments.com.au 25 October 2018 Highlights EVE INVESTMENTS QUARTERLY UPDATE FOR THE PERIOD ENDING 30 SEPTEMBER Shareholder agreement to change the scale of
More informationAFT PHARMACEUTICALS Investor Presentation
AFT PHARMACEUTICALS IMPORTANT NOTICE This presentation has been prepared by AFT Pharmaceuticals Limited ( AFT ), to provide a general overview of AFT. It is not prepared for any other purpose and must
More informationKathmandu Holdings Limited FY2018 full year results
Kathmandu Holdings Limited full year results Record year for sales, profit, operating cash flow and full-year dividend payout Sales increased by 11.7% to NZ$497.4m Gross profit increased by 14.2% to NZ$315.5m
More information19 March Goodman Fielder New Zealand Limited 31 December 2011 Half Year Report
Company No. 1508360 19 March 2012 2/8 Nelson Street Auckland, New Zealand 1010 PO Box 90450, Victoria Street West Auckland, New Zealand 1142 www.goodmanfielder.co.nz Listed Company Relations New Zealand
More informationInterim Report and Accounts
Interim Report and Accounts FOR THE HALF YEAR ENDED 30 SEPTEMBER Mulberry Interim Report and Accounts Six months ended FINANCIAL HIGHLIGHTS Total revenue up 10% to 74.5 million (: 67.8 million) Strong
More informationSCALES CORPORATION LIMITED GROWING YOUR DIVERSIFIED AGRIBUSINESS
SCALES CORPORATION LIMITED GROWING YOUR DIVERSIFIED AGRIBUSINESS 2018 Annual Shareholders Meeting 13 AGENDA Welcome Chairman s review Managing Director s review Ordinary business and resolutions 2 CHAIRMAN
More information2007 Full-year results presentation. Analysts & Media Conference Basel, 7 February 2008
2007 Full-year results presentation Analysts & Media Conference Basel, Disclaimer This presentation contains certain forward-looking statements, which can be identified by use of terminology such as expect,
More informationLupin Investor Presentation Q3FY14
Lupin Investor Presentation Q3FY14 Vision: To be an innovation led transnational company Safe harbor statement Materials and information provided during this presentation may contain forward looking statements.
More informationMayne Pharma Group Limited
Mayne Pharma Group Limited HY14 Results Presentation 26 February 2014 Scott Richards, Chief Executive Officer Mark Cansdale, Group CFO Disclaimer The information provided is general in nature and is in
More informationJUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS
PRESS RELEASE Noida, Tuesday, May 24, 2016 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS JUBILANT
More informationInterim Results For 6 months ended 31 Dec February 2018
Interim Results For 6 months ended 31 Dec 2017 February 2018 Financial highlights 62.5m 55.7m 71.7m 13.7m 10.8m 15.8m 8.8m 11.2m 12.9m 16 17 18 16 17 18 16 17 18 REVENUE 71.7m (H1 FY17: 62.5m) +14.7% YEAR-ON-YEAR
More informationYEAR END REPORT 30 JUNE
YEAR END REPORT 30 JUNE 13 IMPORTANT NOTICE AND DISCLAIMER This presentation has been prepared by Specialty Fashion Group Limited (the Company ). It contains general background information about the Company
More informationCroda International Plc 2014 Interim Results. 22 July 2014
Croda International Plc 2014 Interim Results 22 July 2014 Introduction Steve Foots Group Chief Executive Underlying progress in a tough environment Constant currency turnover up 2.3% 5 out of 8 core markets
More informationFor personal use only
Freedom Foods Group Limited Presentation to Morgan's Conference October 2016 Important Information This presentation is provided for information purposes only. The information contained in this presentation
More informationOverview. Highlights. Financial highlights
Injectables Our Injectables business manufactures, markets and sells generic injectable products in the US, the MENA region and Europe. In the US, we are the third largest manufacturer of injectables by
More informationFull Year results and outlook
PRESENTATION TO INVESTORS & ANALYSTS Full Year results and outlook David Banfield, Group CEO 29 August 2018 for 12 months 1 July 2017 30 June 2018 Strong international performance drives double digit earnings
More informationSamsonite International S.A.
Samsonite International S.A. 13 15 avenue de la Liberté, L-1931 Luxembourg R.C.S. Luxembourg: B 159.469 (Incorporated under the laws of Luxembourg with limited liability) Consolidated financial statements
More informationStandard Chartered first half profit up 9% to US$3.95bn
Standard Chartered first half profit up 9% to US$3.95bn Strong momentum combined with diversity of performance provides real resilience Highlights: Group income climbs 9%, with growth across our markets.
More informationSamsonite International S.A. Announces 2013 Final Results Net sales top a record US$2 billion for the first time
(Incorporated in Luxembourg with limited liability) (Stock code: 1910) Samsonite International S.A. Announces 2013 Final Results Net sales top a record US$2 billion for the first time Highlights Samsonite
More informationMethven Group Interim Results Outperform Guidance
NZX Statement November 2009 30 Methven Group Interim Results Outperform Guidance Performance Summary Methven Group outperforms half year guidance Net Debt down 47.4% from $35.0M to $18.3M, better than
More informationTHINKSMART 2009 Half Year Results Presentation: 21 st August 2009
THINKSMART 2009 Half Year Results Presentation: 21 st August 2009 Ned Montarello Executive Chairman & CEO Neil Barker Group COO Agenda 1. The ThinkSmart Business 2. Half Year Scorecard 3. Key Financial
More informationSamsonite International S.A. Announces 2013 Interim Results
Samsonite International S.A. Announces 2013 Interim Results Highlights Samsonite s net sales for the six months ended June 30, 2013 increased by 16.5% 1 to another record US$983.6 million with growth across
More informationRakon Limited. Annual Report 2018
Rakon Limited Annual Report 2018 Table of Contents Directors Report 3 Statement of Comprehensive Income 4 Statement of Changes in Equity 5 Balance Sheet 6 Statement of Cash Flows 7 Notes to the Financial
More informationFor personal use only
26 October 2018 ASX Code: MXC September 2018 Quarterly Activity Report Key milestones achieved towards MXC achieving its goal as a leading medicinal cannabis Bio-Pharma company GMP Certification and Manufacturing
More informationPlexure Group Limited
Plexure Group Limited Directory As at 30 September 2016 Company Number 244518 NZ Business Number 9429039937803 Directors Registered Office Phil Norman - Chairman Scott Bradley Mike Carden Tim Cook Sharon
More informationMoberg Pharma AB PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES. Corporate presentation Aktiespararna Södertälje, April 18 th 2016 Anna Ljung, CFO
Moberg Pharma AB PROVIDING UNIQUE PRODUCTS IN UNDERSERVED NICHES Corporate presentation Aktiespararna Södertälje, April 18 th 2016 Anna Ljung, CFO 0 Disclaimer Statements included herein that are not historical
More informationFor personal use only ABN
ABN 89 106 523 611 Appendix 4D Half year report In compliance with ASX Listing Rule 4.2.A.3 For the period ended 31 December 2017 Results for Announcement to the Market Half year ended 31 Dec 17 Up / Down
More information